<div>
<h2>Key Points</h2><ul><li>ACT Capital Management acquired 174,250 ALMS shares in the first quarter, with an estimated trade value of $4.36 million based on average first-quarter pricing.</li><li>The quarter-end position value was $3.84 million, reflecting the value of the newly established position.</li><li>The transaction represented a 3.42% change relative to ACT Capital Management’s 13F reportable assets.</li><li>10 stocks we like better than Alumis ›</li></ul><p>On May 8, 2026, ACT Capital Management disclosed a new position in <strong>Alumis</strong> <span class="ticker">(NASDAQ:ALMS)</span>, acquiring 174,250 shares in a trade estimated at $4.36 million based on quarterly average pricing.</p><h2 id="what-happened">What happened</h2><p>According to a Securities and Exchange Commission (SEC) filing dated May 8, 2026, ACT Capital Management opened a new position in Alumis by purchasing 174,250 shares. The estimated value of this acquisition is $4.36 million, based on the average unadjusted closing price during the quarter. The quarter-end valuation of the position stood at $3.84 million, reflecting both share count and market price changes.</p><h2 id="what-else-to-know">What else to know</h2><ul><li>This was a new position for ACT Capital Management and represented 3.02% of its 13F reportable assets at quarter’s end.</li><li>Top five holdings after the filing:<ul><li>NASDAQ:KRYS: $15.62 million (12.3% of AUM)</li><li>NYSE:CVX: $15.52 million (12.2% of AUM)</li><li>NYSE:XOM: $11.88 million (9.3% of AUM)</li><li>NASDAQ:CELC: $10.46 million (8.2% of AUM)</li><li>NASDAQ:TGTX: $8.27 million (6.5% of AUM)</li></ul></li><li>As of May 7, 2026, Alumis shares were priced at $23.76, up a staggering 350% over the past year and vastly outperforming the S&amp;P 500’s roughly 30% gain in the same period.</li></ul><h2 id="company-overview">Company overview</h2><section><table><tbody><tr><th>Metric</th><th>Value</th></tr><tr><td>Market capitalization</td><td>$3 billion</td></tr><tr><td>Revenue (TTM)</td><td>$24.05 million</td></tr><tr><td>Net income (TTM)</td><td>($243.32 million)</td></tr></tbody></table></section><h2 id="company-snapshot">Company snapshot</h2><ul><li>Alumis develops clinical-stage medicines targeting autoimmune and neuroinflammatory disorders, with lead candidates including ESK-001 and A-005 focused on TYK2 inhibition.</li><li>The firm operates a biopharmaceutical business model, generating revenue through the development and potential commercialization of novel therapeutics for chronic immune-related diseases.</li><li>It targets healthcare providers and patients affected by autoimmune and neurodegenerative conditions, with a focus on indications such as plaque psoriasis and systemic lupus erythematosus.</li></ul><p>Alumis is a clinical-stage biotechnology company specializing in the development of innovative therapies for autoimmune and neuroinflammatory diseases. The company leverages allosteric TYK2 inhibition technology to address unmet medical needs in chronic immune disorders. With a focused pipeline and a strategy centered on differentiated drug candidates, Alumis aims to establish a competitive position in the biopharmaceutical sector.</p><h2 id="what-this-transaction-means-for-investors">What this transaction means for investors</h2><p>Alumis shares have already surged roughly 350% over the past year, but ACT Capital still initiated a position that immediately became more than 3% of assets under management. That suggests conviction around upcoming drug catalysts and the broader commercial potential of the company’s TYK2 pipeline.<br/><br/>In March, Alumis reported positive Phase 3 data for envudeucitinib in moderate-to-severe plaque psoriasis, with roughly 65% of patients achieving PASI 90 skin clearance and more than 40% achieving PASI 100 at Week 24. The company plans to submit an NDA in the second half of 2026 and expects potentially pivotal Phase 2b lupus data in the third quarter.<br/><br/>Alumis also strengthened its balance sheet in January with a $345 million stock offering and finished 2025 with $308.5 million in cash and marketable securities, which coincided with a massive stock surge.<br/><br/>For long-term investors, the opportunity here is obvious, but so is the risk. Alumis has promising data and multiple near-term catalysts, though the company still posted a $243 million net loss last year as research spending accelerated. Upcoming results will ultimately determine the stock’s trajectory.</p><h2>Should you buy stock in Alumis right now?</h2>
<p>Before you buy stock in Alumis, consider this:</p>
<p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Alumis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $471,827</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,319,291</strong>!*</p>
<p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 986<span>% — a market-crushing outperformance compared to 207% for the S&amp;P 500. <strong><span>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</span></strong></span></p>
<p>See the 10 stocks »</p>
<p style="color: #767676; text-align: left"><em>*Stock Advisor returns as of May 10, 2026. </em></p><p><em>Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron and Krystal Biotech. The Motley Fool recommends TG Therapeutics. The Motley Fool has a disclosure policy.</em></p>
<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
</div>

ALMS

<p>ACT Capital Management has acquired 174,250 shares of Alumis (NASDAQ:ALMS) for approximately $4.36 million, representing 3.02% of its reportable assets. The shares have surged 350% over the past year, driven by positive Phase 3 data for its drug targeting plaque psoriasis. Alumis, a clinical-stage biotechnology firm, focuses on autoimmune and neuroinflammatory disorders. Despite a $243 million net loss last year, the company has a strong cash position and upcoming drug catalysts, making it a potential investment opportunity, though risks remain.</p>

nasdaq

Alumis

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VG Health

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

iShares Biotechnology ETF

SPDR S&P Biotech

Krystal Biotech

Chevron

Exxon Mobil

Celcuity

TG Therap

S&P 500

Netflix

NVIDIA

NVIDIA Corporation

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug